$1.49
+0.03 (+2.05%)
Open$1.47
Previous Close$1.46
Day High$1.52
Day Low$1.46
52W High$19.03
52W Low$0.97
Volume—
Avg Volume65.2K
Market Cap7.69M
P/E Ratio—
EPS$-6.03
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+433.6% upside
Current
$1.49
$1.49
Target
$7.95
$7.95
$5.82
$7.95 avg
$9.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 913.8K | 821.5K | 988.8K |
| Net Income | -134,164 | -149,522 | -162,197 |
| Profit Margin | -14.7% | -18.2% | -16.4% |
| EBITDA | -201,888 | -178,889 | -216,043 |
| Free Cash Flow | -124,461 | -98,758 | -111,181 |
| Rev Growth | +16.4% | +11.0% | +21.1% |
| Debt/Equity | 1.08 | 0.86 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |